Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Cohort, Placebo-Controlled, Inpatient Phase 1b Dose-Ranging Trial Evaluating the Safety and Tolerability of KarXT (Trospium-chloride/xanomeline) in Healthy Elderly Volunteers

Next Previous
Trial Profile

A Multi-Cohort, Placebo-Controlled, Inpatient Phase 1b Dose-Ranging Trial Evaluating the Safety and Tolerability of KarXT (Trospium-chloride/xanomeline) in Healthy Elderly Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 23 Jun 2021 According to a Karuna Therapeutics media release, the company plans to evaluate pharmacokinetic data from Cohort 3, once available. Results from the third cohort provide additional data to finalize the dosing and titration protocol for phase II trial.
  • 23 Jun 2021 Results published in the Karuna Therapeutics Media Release.
  • 23 Jun 2021 Results published in the Karuna Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top